Skin cancer risk among patients with type 2 diabetes treated with hydrochlorothiazide

The use of hydrochlorothiazide and skin cancer risk among patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON28736

Enrollment

71648

Registered

2020-02-06

Start date

1998-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes, hypertension, skin cancer

Interventions

Exposure to hydrochlorothiazide

Eligibility

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients treated in the primary care

Exclusion criteria

Exclusion criteria: Type 2 diabtes patientes who had a history of skin cancer before cohort entry

Design outcomes

Primary

Measure	Time frame
Hazard ratio of skin cancer risk exposing to hydrochlorothiazide compared with no expose to hydrochlorothiazide	—

Secondary

Measure	Time frame
Existence of exposure-time-response relationship	—

Contacts

Public ContactJing Du

university medical center groningen

j.du@umcg.nl0682300571

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)